The independent effect of drug resistance on T cell activation in HIV infection

No abstract is available for this paper.

• Publication year

  2006

• Venue

  AIDS (London)

• Publication date

  2006-03-21

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/01.aids.0000216369.30948.18PMID 16514299
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2022 update of the drug resistance mutations in HIV-1.

  2022cited by this paper
• Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection.

  2005cited by this paper
• Coupling of Human Immunodeficiency Virus Type 1 Fusion to Virion Maturation: a Novel Role of the gp41 Cytoplasmic Tail

  2004cited by this paper
• Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load.

  2004cited by this paper
• Extracellular Nef Protein Targets CD4+ T Cells for Apoptosis by Interacting with CXCR4 Surface Receptors

  2004cited by this paper
• Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1.

  2004cited by this paper
• Update of the drug resistance mutations in HIV-1: 2004.

  2004cited by this paper
• Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia.

  2003cited by this paper
• HIV-1–Infected Antiretroviral-Treated Patients With Prolonged Partial Viral Suppression: Clinical, Virologic, and Immunologic Course

  2003cited by this paper
• Discordant Outcomes following Failure of Antiretroviral Therapy Are Associated with Substantial Differences in Human Immunodeficiency Virus-Specific Cellular Immunity

  2003cited by this paper
• T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy.

  2003cited by this paper
• Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions

  2003cited by this paper
• Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions

  2003cited by this paper
• Dual Pressure from Antiretroviral Therapy and Cell-Mediated Immune Response on the Human Immunodeficiency Virus Type 1 Protease Gene

  2003cited by this paper
• Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control.

  2003cited by this paper
• Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy

  2002cited by this paper
• Reduced levels of CD4 cell spontaneous apoptosis in human immunodeficiency virus-infected patients with discordant response to protease inhibitors.

  2002cited by this paper
• Discordant responses during antiretroviral therapy: role of immune activation and T cell redistribution rather than true CD4 T cell loss.

  2002cited by this paper
• Effects of Antiretroviral Drugs on Human Immunodeficiency Virus Type 1-Induced CD4+ T-Cell Death

  2002cited by this paper
• CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy.

  2002cited by this paper
• CD4 T Cell Depletion Is Linked Directly to Immune Activation in the Pathogenesis of HIV-1 and HIV-2 but Only Indirectly to the Viral Load1

  2002cited by this paper
• Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia

  2002cited by this paper
• Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts.

  2002cited by this paper
• Predictive Value of Immunologic and Virologic Markers After Long or Short Duration of HIV‐1 Infection

  2002cited by this paper
• The influence of host HLA on antiretroviral drug resistance mutation in HIV-1

  2002cited by this paper
• Discordant CD4 T lymphocyte responses to antiretroviral therapy for HIV infection are associated with ex-vivo rates of apoptosis.

  2001cited by this paper
• Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen.

  2001cited by this paper
• Decreased HIV-Associated T Cell Apoptosis by HIV Protease Inhibitors

  2000cited by this paper
• Increased levels of activated subsets of CD4 T cells add to the prognostic value of low CD4 T cell counts in a cohort of HIV-infected drug users

  2000cited by this paper
• Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy

  2000cited by this paper
• Quantitative and Cost Comparison of Ultrasensitive Human Immunodeficiency Virus Type 1 RNA Viral Load Assays: Bayer bDNA Quantiplex Versions 3.0 and 2.0 and Roche PCR Amplicor Monitor Version 1.5

  2000cited by this paper
• Effect of Zidovudine on the Primary Cytolytic T-Lymphocyte Response and T-Cell Effector Function

  2000cited by this paper
• 3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine

  2000cited by this paper
• Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions

  1999cited by this paper
• HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages

  1999cited by this paper
• Human immunodeficiency virus 1 protease inhibitors in clinical practice: predictors of virological outcome.

  1999cited by this paper
• Relations among CD4 Lymphocyte Count Nadir, Antiretroviral Therapy, and HIV-1 Disease Progression: Results from the EuroSIDA Study

  1999cited by this paper
• Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo.

  1999cited by this paper
• Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients : a prospective cohort study

  1999cited by this paper
• Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study.

  1999cited by this paper
• Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage.

  1999cited by this paper
• HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy.

  1999cited by this paper
• Quantitation of CD38 expression using QuantiBRITE beads.

  1998cited by this paper
• Regions of Human Immunodeficiency Virus Type 1nef Required for Function In Vivo

  1998cited by this paper
• The Proteolytic Cleavage of Human Immunodeficiency Virus Type 1 Nef Does Not Correlate with Its Ability To Stimulate Virion Infectivity

  1998cited by this paper
• CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency.

  1998cited by this paper
• Induction of CD4+ T cell depletion in mice doubly transgenic for HIV gp120 and human CD4

  1997cited by this paper
• Human immunodeficiency virus type 1 gp120 induces anergy in human peripheral blood lymphocytes by inducing interleukin-10 production

  1996cited by this paper
• Induction of lymphomonocyte activation by HIV-1 glycoprotein gp120. Possible role in AIDS pathogenesis.

  1996cited by this paper
• Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120

  1995cited by this paper
• Differential susceptibility to monomeric HIV gp120‐mediated apoptosis in antigen‐activated CD4+ T cell populations

  1995cited by this paper
• HIV-1 gp120 and anti-gp120 induce reversible unresponsiveness in peripheral CD4 T lymphocytes.

  1994cited by this paper
• HIV‐1 gp120‐dependent induction of apoptosis in antigen‐specific human T cell clones is characterized by ‘tissue’ transglutaminase expression and prevented by cyclosporin A

  1994cited by this paper
• Processing protease for gp160 human immunodeficiency virus type I envelope glycoprotein precursor in human T4+ lymphocytes. Purification and characterization.

  1993cited by this paper
• Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis

  1992cited by this paper
• HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

  1989cited by this paper
• Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus.

  1988cited by this paper

• Multifactorial determinants of lost to follow-up in antiretroviral therapy: evidence from a case–control study in Mexico

  2026cites this paper
• Thalidomide is Associated With Increased T Cell Activation and Inflammation in Antiretroviral-naive HIV-infected Individuals in a Randomised Clinical Trial of Efficacy and Safety

  2017cites this paper
• Long-term effects of HIV treatment in sub-Saharan Africa: from access to quality

  2016cites this paper
• Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.

  2015cites this paper
• Association between Latent Proviral Characteristics and Immune Activation in Antiretrovirus-Treated Human Immunodeficiency Virus Type 1-Infected Adults

  2014cites this paper
• Pediatric human immunodeficiency virus infection and cancer in the highly active antiretroviral treatment (HAART) era.

  2014cites this paper
• Drug-resistant virus has reduced ability to induce immune activation.

  2012cites this paper
• Nucleic Acid Testing for HIV-1 Diagnosis and Monitoring

  2012cites this paper
• Substance use and HIV disease progression in the HAART era: implications for the primary prevention of HIV.

  2011cites this paper
• Immune Activation, Cd4+ T Cell Counts, and Viremia Exhibit Oscillatory Patterns over Time in Patients with Highly Resistant HIV Infection

  2011cites this paper
• The Impact of Highly Active Antiretroviral Treatment on the Blood Profiles of Patients with Acquired Immune Deficiency Syndrome

  2011cites this paper
• Mortality Associated With Discordant Responses to Antiretroviral Therapy in Resource-Constrained Settings The Antiretroviral Therapy in Low Income Countries (ART-LINC) Collaboration of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) *

  2011cites this paper
• HIV Type 1 Antiretroviral Resistance Mutations in Subtypes B, C, and F in the City of São Paulo, Brazil

  2010cites this paper
• Immune activation in chronic HIV infection.

  2010cites this paper
• Factors associated with collagen deposition in lymphoid tissue in long-term treated HIV-infected patients

  2010cites this paper
• Mortality Associated With Discordant Responses to Antiretroviral Therapy in Resource-Constrained Settings

  2010cites this paper
• Therapeutic Immunization with HIV-1 Tat Reduces Immune Activation and Loss of Regulatory T-Cells and Improves Immune Function in Subjects on HAART

  2010cites this paper
• Patients with Discordant Responses to Antiretroviral Therapy Have Impaired Killing of HIV-Infected T Cells

  2010cites this paper
• Coreceptor expression and T lymphocyte subset distribution in HIV-infected and TB co-infected South African patients on anti-retroviral therapy

  2009cites this paper
• The predictive value of CD38 positive hepatic stellate cell count for assessing disease activity and fibrosis in patients with chronic hepatitis.

  2009cites this paper
• Estratègies de simplificació del tractament antiretroviral en diferents estadiatges de la infecció pel VIH-1

  2009cites this paper
• Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection.

  2009cites this paper
• Stimulant use is associated with immune activation and depleted tryptophan among HIV-positive persons on anti-retroviral therapy.

  2008cites this paper
• Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.

  2008cites this paper
• Antiretroviral Treatment Effect on Immune Activation Reduces Cerebrospinal Fluid HIV-1 Infection

  2008cites this paper
• PD-1 predicts CD4 loss rate in chronic HIV-1 infection better than HIV RNA and CD38 but not in cryopreserved samples.

  2008cites this paper
• Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV‐1‐infected patients with multidrug‐resistant virus: a multicentre pilot study

  2008cites this paper
• Effectiveness of Highly Active Antiretroviral Therapy in HIV patients in resource-limited settings

  2008cites this paper
• Social Memory, Maternal Care, and Oxytocin Secretion, But not Vasopressin Release, Require CD38 In Mice

  2008cites this paper
• Dysfunctional natural killer cells, in vivo, are governed by HIV viremia regardless of whether the infected individual is on antiretroviral therapy.

  2007cites this paper
• Flying in the Face of Resistance: Antiviral‐independent Benefit of HIV Protease Inhibitors on T‐cell Survival

  2007cites this paper
• Role of immune activation in HIV pathogenesis

  2007cites this paper
• Preexposure prophylaxis for HIV infection: it's not as easy as ABC.

  2007cites this paper
• Partial treatment interruptions.

  2007cites this paper
• Monitoring clinical trials of therapeutic vaccines in HIV infection: role of treatment interruption

  2007cites this paper
• Current World Literature

  2007cites this paper
• Evidence for the importance of immune activation in the pathogenesis of HIV disease

  2007cites this paper
• The rationale for immunosuppressive therapy for HIV infection

  2007cites this paper
• Immune reconstitution in human immunodeficiency virus type 1‐infected children with different virological responses to anti‐retroviral therapy

  2007cites this paper
• A Randomized Study of Antiviral Medication Switch at Lower-Versus Higher-Switch Thresholds: AIDS Clinical Trials Group Study A5115

  2007cites this paper
• CD38 is critical for social behaviour by regulating oxytocin secretion

  2007cites this paper
• Drug resistance mutations and the cellular immune response: a valuable synergy for the development of novel immune therapies

  2007cites this paper
• Dissecting the Reasons for Immunologic Stability Despite Virologic Failure

  2006cites this paper
• Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen.

  2006cites this paper
• An update on HIV-1 antiretroviral resistance

  2006cites this paper